| Autor: |
Bratova M; Department of Respiratory Diseases, University Hospital Brno, Brno, Czech Republic.; Faculty of Medicine, Masaryk University, Brno, Czech Republic., Brat K; Department of Respiratory Diseases, University Hospital Brno, Brno, Czech Republic.; Faculty of Medicine, Masaryk University, Brno, Czech Republic., Hurdalkova K; Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic., Barinova M; Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic., Drosslerova M; Department of Respiratory Medicine, Thomayer University Hospital, Prague, Czech Republic.; 1st Faculty of Medicine, Charles University, Praque, Czech Republic., Kultan J; Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic.; Faculty of Medicine, Palacky University, Olomouc, Czech Republic., Wanke M; Department of Pneumology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.; Faculty of Medicine, Charles University in Prague, Hradec Kralove, Czech Republic., Koubkova L; Department of Pneumology, University Hospital Motol, Prague, Czech Republic.; 2nd Faculty of Medicine, Charles University, Prague, Czech Republic., Krejci J; Department of Pneumology and Thoracic Surgery, Bulovka Hospital, Prague, Czech Republic., Svaton M; Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic.; Faculty of Medicine, Charles University in Prague, Pilsen, Czech Republic. |
| Abstrakt: |
Purpose: Aim was to analyze demographic and tumor characteristics, treatment, and survival of patients with lung cancer younger than 40 years of age (U40) compared to older subgroups (41-70 and >70 years). Methods: We analyzed data of young patients diagnosed and treated in 2011-2019 in five pneumo-oncology centers in Czechia. Standard descriptive statistics, chi-squared test, Fisher exact test, and Kaplan-Meier survival analysis were used. p -Values <0.05 were considered significant. These data were compared with two control subgroups (cohort 1: 41-70 years, cohort 2: >70 years). Results: We identified 66 patients U40, 61 with non-small cell lung cancer (NSCLC)-50.8% men, mean age 34.6 years, 54.1% nonsmokers, daily good performance status, and 82% in stage IV. Adenocarcinomas dominated, endothelial growth factor receptor (EGFR) positivity was less common than in older groups contrary to anaplastic lymphoma kinase (ALK) mutations. Median progression-free survival was 3.7 months (vs. 4.9 and 6.2 months; p = 0.006) and overall survival reached 11.7 months (vs. 22.3 and 27.3 months; p < 0.001). Young patients in stage IV and never-smokers had shorter survival than older patients. Conclusion: Patients with NSCLC U40 had significantly worse prognosis than older patients. |
